OBJECTIVE:To systematically evaluate the efficacy and safety of Chinese herbal medicine(CHM) combined with conventional Western Medicine(CWM) on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) base...OBJECTIVE:To systematically evaluate the efficacy and safety of Chinese herbal medicine(CHM) combined with conventional Western Medicine(CWM) on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) based on high-quality randomized placebocontrolled trials.METHODS:We searched PubMed,Embase,Cochrane Library,China National Knowledge Infrastructure Database,Chinese Biomedical Literature Database,China Science and Technology Journal Database,and Wanfang databases for randomized placebo-controlled trials of CHM treatment for AECOPD from inception to June 4,2021.The Cochrane Collaboration’s tool and the Grading of Recommendations,Assessment,Development and Evaluation were used to assess the risk of bias and the evidence quality of the included studies.Revman 5.3 software was used for Meta-analysis.RESULTS:A total of 9 trials involving 1591 patients were included.The Meta-analysis showed that based on CWM treatment,CHM group had significant advantages over the placebo group in ameliorating clinical total effective rate [RR = 1.29,95% CI(1.07,1.56),P = 0.007,low quality] and TCM symptom scores [MD =-2.99,95% CI(-4.46,-1.53),P < 0.0001,moderate quality],improving arterial blood gas results [PaO_(2):MD = 4.51,95% CI(1.97,7.04),P = 0.0005,moderate quality;PaCO_(2):MD =-2.87,95% CI(-4.28,-1.46),P < 0.0001,moderate quality],reducing CAT scores [MD =-2.08,95% CI(-2.85,-1.31),P < 0.000 01,moderate quality],length of hospitalization [MD =-1.87,95% CI(-3.33,-0.42),P = 0.01,moderate quality],and acute exacerbation rate [RR = 0.60,95% CI(0.43,0.83),P = 0.002,moderate quality].No serious CHM-related adverse events were reported.CONCLUSIONS:The current evidence indicates that CHM is an effective and well-tolerated adjunct therapy for AECOPD patients receiving CWM.However,considering the high heterogeneity,this conclusion requires confirmation.展开更多
文摘目的:系统评价镇肝熄风汤治疗帕金森病的疗效及安全性。方法:计算机检索主要的中英文医学数据库,全面收集镇肝熄风汤治疗帕金森病的临床随机对照试验,采用Cochrane handbook 5.1.0中的偏倚风险评估工具对纳入文献进行偏倚风险评估,用Rev Man 5.3软件进行统计和Meta分析,并按照国际证据评价与推荐GRADE标准进行质量评价。结果:共纳入6个研究包括498例病例。Meta分析结果显示,帕金森病评定量表总评分(UPDRS):根据干预措施不同,进行亚组分析,镇肝熄风汤VS美多巴(MD=-9.03,95%CI[-11.83,-6.23]),镇肝熄风汤联合美多巴vs美多巴(MD=-5.21,95%CI[-9.52,-0.90]);UPDRSⅠ+Ⅱ+Ⅲ总评分:镇肝熄风汤联合美多巴、美多巴+常规西药vs美多巴、美多巴+常规西药(MD=-5.21,95%CI[-9.52,-0.90]);差异均有统计学意义。但UPDRSⅡ+Ⅲ总评分(MD=-7.18,95%CI[-15.71,1.35]),差异无统计学意义。治疗有效率,采用UPDRS减分率计算有效率的Meta分析结果显示,镇肝熄风汤联合常规西药vs常规西药(RR=1.32,95%CI[1.09,1.61]),差异有统计学意义。共有4篇研究报道不良事件或不良反应。根据GRADE方法评价,该证据质量评价为低级。结论:镇肝熄风汤或镇肝熄风汤联合美多巴、美多巴+常规西药效果均优于美多巴、美多巴+常规西药。但由于本系统评价纳入研究的方法学质量较低,且例数较少,证据质量级别较低,因此临床医生使用该证据进行临床决策时尚需谨慎。
基金Supported by the National Natural Science:Research on Key Technology of Outcome Measurement and Evaluation of Syndrome Differentiation and Treatment Based on Clinical Trials of COPD (No. 81830116)the Chinese Medicine Inheritance and Innovation “Hundred and Ten Million” Talent ProjectChief Scientist of Qi-Huang Project [(2020) No. 219]the Zhong-yuan Scholars and Scientists Project (No. 2018204)。
文摘OBJECTIVE:To systematically evaluate the efficacy and safety of Chinese herbal medicine(CHM) combined with conventional Western Medicine(CWM) on acute exacerbation of chronic obstructive pulmonary disease(AECOPD) based on high-quality randomized placebocontrolled trials.METHODS:We searched PubMed,Embase,Cochrane Library,China National Knowledge Infrastructure Database,Chinese Biomedical Literature Database,China Science and Technology Journal Database,and Wanfang databases for randomized placebo-controlled trials of CHM treatment for AECOPD from inception to June 4,2021.The Cochrane Collaboration’s tool and the Grading of Recommendations,Assessment,Development and Evaluation were used to assess the risk of bias and the evidence quality of the included studies.Revman 5.3 software was used for Meta-analysis.RESULTS:A total of 9 trials involving 1591 patients were included.The Meta-analysis showed that based on CWM treatment,CHM group had significant advantages over the placebo group in ameliorating clinical total effective rate [RR = 1.29,95% CI(1.07,1.56),P = 0.007,low quality] and TCM symptom scores [MD =-2.99,95% CI(-4.46,-1.53),P < 0.0001,moderate quality],improving arterial blood gas results [PaO_(2):MD = 4.51,95% CI(1.97,7.04),P = 0.0005,moderate quality;PaCO_(2):MD =-2.87,95% CI(-4.28,-1.46),P < 0.0001,moderate quality],reducing CAT scores [MD =-2.08,95% CI(-2.85,-1.31),P < 0.000 01,moderate quality],length of hospitalization [MD =-1.87,95% CI(-3.33,-0.42),P = 0.01,moderate quality],and acute exacerbation rate [RR = 0.60,95% CI(0.43,0.83),P = 0.002,moderate quality].No serious CHM-related adverse events were reported.CONCLUSIONS:The current evidence indicates that CHM is an effective and well-tolerated adjunct therapy for AECOPD patients receiving CWM.However,considering the high heterogeneity,this conclusion requires confirmation.
